OncLive.com· @OncLive · X·· 1 天前评分70
正文 · 原文
It's time!! The second Presidential Symposium is officially underway. Check back tonight for live coverage of Krascendo 1, SAFFRON, CLARITY-Gastric 01, and HARMONi-GI1 @myESMO #ESMO26 #Oncology
111 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org来源:OncLive.com · x.com
